Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.

Tan X, Tsai WL, Liang Y, Swift C, Fang G, Muhammad C, de Havenon A

Advances in therapy30 Apr 2026

PMID42060161PMCIDPMC13290940DOI10.1007/s12325-026-03610-7PepBankPUB-42060161

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who reached glycemic and weight goals, LDL cholesterol fell at 1 and 2 years after semaglutide initiation (all p < 0.001).
In plain wordsIn adults with type 2 diabetes who reached their goals, LDL cholesterol was lower 1 and 2 years after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLDL-C change
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Significant reductions were observed in low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), total cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure and high-density lipoprotein cholesterol (HDL-C) increased at both 1 and 2 y…
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016101
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who reached glycemic and weight goals, VLDL cholesterol fell at 1 and 2 years after semaglutide initiation (all p < 0.001).
In plain wordsIn adults with type 2 diabetes who reached their goals, VLDL cholesterol was lower 1 and 2 years after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseVLDL-C change
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Significant reductions were observed in low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), total cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure and high-density lipoprotein cholesterol (HDL-C) increased at both 1 and 2 y…
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016102
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who reached glycemic and weight goals, total cholesterol fell at 1 and 2 years after semaglutide initiation (all p < 0.001).
In plain wordsIn adults with type 2 diabetes who reached their goals, total cholesterol was lower 1 and 2 years after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseTotal cholesterol change
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Significant reductions were observed in low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), total cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure and high-density lipoprotein cholesterol (HDL-C) increased at both 1 and 2 y…
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016103
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who reached glycemic and weight goals, triglycerides fell at 1 and 2 years after semaglutide initiation (all p < 0.001).
In plain wordsIn adults with type 2 diabetes who reached their goals, triglycerides were lower 1 and 2 years after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseTriglycerides change
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Significant reductions were observed in low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), total cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure and high-density lipoprotein cholesterol (HDL-C) increased at both 1 and 2 y…
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016104
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who reached glycemic and weight goals, HDL cholesterol increased at 1 and 2 years after semaglutide initiation (all p < 0.001).
In plain wordsIn adults with type 2 diabetes who reached their goals, HDL cholesterol was higher 1 and 2 years after starting semaglutide.
Peptide
Semaglutide
Outcome
IncreaseHDL-C change
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Significant reductions were observed in low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), total cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure and high-density lipoprotein cholesterol (HDL-C) increased at both 1 and 2 y…
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016105
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who reached glycemic and weight goals, systolic blood pressure fell at 1 and 2 years after semaglutide initiation (all p < 0.001).
In plain wordsIn adults with type 2 diabetes who reached their goals, systolic blood pressure was lower 1 and 2 years after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure change
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Significant reductions were observed in low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), total cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure and high-density lipoprotein cholesterol (HDL-C) increased at both 1 and 2 y…
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016106
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who reached glycemic and weight goals, diastolic blood pressure fell at 1 and 2 years after semaglutide initiation (all p < 0.001).
In plain wordsIn adults with type 2 diabetes who reached their goals, diastolic blood pressure was lower 1 and 2 years after starting semaglutide.
Peptide
Semaglutide
Outcome
DecreaseDiastolic blood pressure change
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Significant reductions were observed in low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL-C), total cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure and high-density lipoprotein cholesterol (HDL-C) increased at both 1 and 2 y…
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016107
08HumanObservational studySafety outcome
In adults with type 2 diabetes who reached glycemic and weight goals, fewer than 1% had a 40% or greater decline in eGFR during follow-up after semaglutide initiation.
In plain wordsIn adults with type 2 diabetes who reached their goals, fewer than 1% had a large drop in kidney function during follow-up on semaglutide.
Peptide
Semaglutide
Outcome
Not applicableDecline of 40% or more in eGFR
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Measurements
Proportion with eGFR decline of 40% or more
< 1%
follow-up
Source sentences
Summary
Fewer than 1% of patients experienced a ≥ 40% decline in estimated glomerular filtration rate (eGFR) during follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016108
09HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who reached glycemic and weight goals, urine albumin-to-creatinine ratio fell after semaglutide initiation, in the 1st year and the 2nd year.
In plain wordsIn adults with type 2 diabetes who reached their goals, a urine marker of kidney damage fell in the first and second years on semaglutide.
Peptide
Semaglutide
Outcome
DecreaseChange in urine albumin-to-creatinine ratio (UACR)
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Measurements
UACR change
−20.13 mg/g
1st year
UACR change
−54.03 mg/g
2nd year
Source sentences
Summary
Mean change in urine albumin-to-creatinine ratio (UACR) were - 20.13 mg/g in the 1st year (p < 0.001) and - 54.03 mg/g in the 2nd year (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016109
10HumanObservational studyEfficacy outcome
In adults with type 2 diabetes who reached glycemic and weight goals, the 3-point MACE rate decreased from baseline to the 2nd year after semaglutide initiation; no test was reported.
In plain wordsIn adults with type 2 diabetes who reached their goals, major heart events were less frequent in year two on semaglutide than before.
Peptide
Semaglutide
Outcome
Decrease3-point MACE event rate
Study
n = 413
Comparator
Baseline (1 year before initiation)
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
3-point MACE rate
26.82 per 1000 PY
baseline
3-point MACE rate
22.31 per 1000 PY
2nd year
Source sentences
Summary
The event rate of 3-point MACE decreased from 26.82 per 1000 person-years (PY) during baseline to 22.31 per 1000 PY in the 2nd year.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary cohort comprised individuals with T2D who achieved glycemic control (HbA1c < 7%) and weight loss (≥ 5%) goals after semaglutide initiation.
Summary · context
We identified 413 patients in the primary cohort (mean age 59.6 years and balanced sex distribution).
Report a problemFND-4206016110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms

Keywords